Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2010

View Archived Issues

Pritumumab is active in patients with brain cancer

GlycoVaxyn reports phase I data on Shigella dysenteriae vaccine

IPI-926 is well tolerated and active in patients with solid tumors

GAA peptide-loaded DC1-based vaccine shows promise in recurrent malignant glioma

French scientists claim new inhibitors of cell division protein kinases

Prosidion describes new GPR119 receptor agonists

Continuous exenatide delivery with ITCA-650 shows promise in phase II diabetes trial

Preclinical and phase I data presented on Algipharma's OligoG

Takeda and Envoy Therapeutics collaborate on schizophrenia research

UCB and Synosia Therapeutics enter into strategic neurology alliance

Novartis renews agreement with WHO to provide free leprosy drugs

Bazedoxifene launched in Japan and Spain for postmenopausal osteoporosis

Almirall presents pharmacological profile of LAS-189913, a new candidate therapeutic for MS

Bristol-Myers Squibb acquires ZymoGenetics

First patient with spinal cord injury is treated in phase I trial of GRNOPC1

FDA funds phase I trial of genetically reprogrammed HSV in childhood cancer

Phase II trial studies sildenafil for heart failure in Duchenne's muscular dystrophy

Pfizer to acquire King Pharmaceuticals and expand pain product portfolio

FDA warns of increased risk of thigh bone fracture with bisphosphonates use

Merck & Co. claims new diacylglycerol O-acyltransferase 1 inhibitors

Olatec Industries patents agents with anti-inflammatory and analgesic potential

New deuterated alpha-(N-sulfonamido)acetamide beta-APP42 production inhibitors claimed

ERYtech and Genzyme to conduct feasibility studies with new therapeutic enzyme formulation

Shire acquires 99.21% of Movetis shares, proceeding with squeeze-out of remaining shares

Twice-daily tramadol/acetaminophen approved in eight European countries

Innate Therapeutics begins phase II trial of MIS-416 in progressive MS

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...